

**OPTIMA HEALTH COMMUNITY CARE  
(MEDICAID)**

**PHARMACY/MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST\***

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-844-348-3720. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If the information provided is NOT complete, correct, or legible, authorization can be delayed.

**Drug Requested:** **Xolair™** (omalizumab) (J-2357) (Medical)  
**Chronic Idiopathic Urticaria (CIU)**

**DRUG INFORMATON:** Complete **all** information below or authorization will be delayed.

**Drug Form/Strength/Month:** \_\_\_\_\_

**Dosing Schedule:** \_\_\_\_\_ **Length of Therapy:** \_\_\_\_\_

**Diagnosis:** \_\_\_\_\_ **ICD Code:** \_\_\_\_\_

**Weight:** \_\_\_\_\_

- **Maximum dosage for Xolair™ Chronic Idiopathic Urticaria - 150mg or 300mg by subcutaneous injection every 4 weeks**

**CLINICAL CRITERIA:** Check below **ALL** that apply. **ALL** criteria **MUST** be met for approval. **ALL** documentation, including lab results and/or chart notes (when required), **must** be provided or request will be denied.

**DIAGNOSIS: Chronic Idiopathic Urticaria. Initial Authorization Length - 12 months**

- Adults and adolescents (> 12 years old) that remain symptomatic despite H1 antihistamine treatment
- Diagnosis for at least > 6 weeks with or without angioedema

**Followed by:**     Allergist        **OR**         Dermatologist

**AND**

- Failed at least **one (1)** H1 antihistamine (4x initial dose) for **4 weeks (check applicable box below):**

<input type="checkbox"/> Levocetirizine 10mg-20mg QD	<input type="checkbox"/> Desloratidine 10-20mg QD	<input type="checkbox"/> Fexofenadine 120mg-240mg BID
<input type="checkbox"/> Cetirizine 20mg-40mg QD	<input type="checkbox"/> Loratadine 20mg-40mg QD	

**AND**

- Patient has remained symptomatic despite treatment with a first generation H1 antihistamine:
  - Hydroxyzine 10mg-25mg QD

(Continued on next page)

**AND**

- Failed at least **one (1)** Leukotriene Antagonist for **4weeks** (check applicable box below):

<input type="checkbox"/> Montelukast 10mg QD	<input type="checkbox"/> Zafirlukast 20mg BID
--	---

**AND**

- Failed H<sub>2</sub> Antihistamine for acute exacerbations at least 5 days:

<input type="checkbox"/> Ranitidine 150mg	<input type="checkbox"/> Famotidine 20mg	<input type="checkbox"/> Cimetidine
---	--	-------------------------------------

**Reauthorization Approval Length – 12 months.** Chart notes and required testing **MUST** be provided with this request form.

- Patient disease status has been re-evaluated since the last authorization to confirm the patient's condition warrants continued treatment. (Chart notes **MUST** be submitted for documentation.)

**AND**

- Patient symptoms has shown improvement (e.g., a decrease in the number of hives, a decrease in the size of hives, and improvement of itching)

**AND**

- The symptoms return when the Xolair™ dose was tapered or withheld beyond the next dosing interval. (Chart notes **must** be submitted for documentation supporting tapering of dose and/or withholding of therapy beyond the next dosing interval to see if symptoms return).

**Medication being provided by (check applicable box below):**

- Physician's office      **OR**       Specialty Pharmacy - PropriumRx

***\*\*Use of samples to initiate therapy does not meet step-edit/ preauthorization criteria\*\****

***\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\****

Patient Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone #: \_\_\_\_\_ Fax #: \_\_\_\_\_

**DEA OR NPI:** \_\_\_\_\_

\*Approved by Pharmacy and Therapeutic Committee: 2/21/2019  
REVISED/UPDATED: 3/23/2019.